Evidence map›Paper›PMID 35815068›Full record

ReviewCurrent research in chemical biology2022

Recent advances on therapeutic potentials of gold and silver nanobiomaterials for human viral diseases.

Yusuf Oloruntoyin Ayipo, Ajibola Abdulahi Bakare, Umar Muhammad Badeggi, Akeem Adebayo Jimoh, Amudat Lawal, Mohd Nizam Mordi

Open access · hybridAbstract readReview
In one paragraph

Review in Current research in chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Yusuf Oloruntoyin AyipoCentre for Drug Research, Universiti Sains Malaysia, 11800, Pulau Pinang, Malaysia.
Ajibola Abdulahi BakareDepartment of Materials and Environmental Technology, Tallinn University of Technology, Ehitajate tee 5, 19086 Tallinn, Estonia.
Umar Muhammad BadeggiDepartment of Chemistry, Ibrahim Badamasi Babangida University Lapai, P. M. B. 11, Minna 4947, Nigeria.
Akeem Adebayo JimohDepartment of Chemistry and Industrial Chemistry, Kwara State University, Malete, P. M. B. 1530, Ilorin 240001, Nigeria.
Amudat LawalDepartment of Chemistry, University of Ilorin, P. M. B. 1515, Ilorin, Nigeria.
Mohd Nizam MordiCentre for Drug Research, Universiti Sains Malaysia, 11800, Pulau Pinang, Malaysia.
Universiti Sains Malaysia · MYCape Peninsula University of Technology · ZAKwara State University · NGTallinn University of Technology · EEUniversity of Ilorin · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral diseases are prominent among the widely spread infections threatening human well-being. Real-life clinical successes of the few available therapeutics are challenged by pathogenic resistance and suboptimal delivery to target sites. Nanotechnology has aided the design of functionalised and non-functionalised Au and Ag nanobiomaterials through physical, chemical and biological (green synthesis) methods with improved antiviral efficacy and delivery. In this review, innovative designs as well as interesting antiviral activities of the nanotechnology-inclined biomaterials of Au and Ag, reported in the last 5 years were critically overviewed against several viral diseases affecting man. These include influenza, respiratory syncytial, adenovirus, severe acute respiratory syndromes (SARS), rotavirus, norovirus, measles, chikungunya, HIV, herpes simplex virus, dengue, polio, enterovirus and rift valley fever virus. Notably identified among the nanotechnologically designed promising antiviral agents include

Indexed as

Bioorganic and bioinorganic synthesisGold and silverNanobiomaterialsNext-generation antiviral therapeuticsViral diseases

Identifiers

PMID35815068
PMCPMC8806017
OpenAlexW4210249653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.